Primary aldosteronism is a common cause of hypertension. Recent evidence suggests that many
patients with bilateral idiopathic hyperaldosteronism harbor gain-of-function somatic
mutations in zona glomerulosa calcium channels that results in aldosterone production. This
finding raises the possibility that calcium channel antagonists may be a targeted therapy to
reduce aldosterone production in patients who harbor these mutations.